欧州連合 -
ノルウェー語 -
EMA (European Medicines Agency)
ozawade
bioprojet pharma - pitolisant - sleep apnea, obstructive - andre nervesystemet narkotika - ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa).
欧州連合 -
ノルウェー語 -
EMA (European Medicines Agency)
sugammadex mylan
mylan ireland limited - sugammadex sodium - neuromuskulær blokkade - alle andre terapeutiske produkter - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
欧州連合 -
ノルウェー語 -
EMA (European Medicines Agency)
sugammadex amomed
aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskulær blokkade - alle andre terapeutiske produkter - reversering av nevromuskulær blokade indusert av rocuronium eller vecuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
欧州連合 -
ノルウェー語 -
EMA (European Medicines Agency)
sugammadex piramal
piramal critical care b.v. - sugammadex sodium - neuromuskulær blokkade - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
欧州連合 -
ノルウェー語 -
EMA (European Medicines Agency)
sugammadex fresenius kabi
fresenius kabi deutschland gmbh - sugammadex sodium - neuromuskulær blokkade - alle andre terapeutiske produkter - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
欧州連合 -
ノルウェー語 -
EMA (European Medicines Agency)
sugammadex adroiq
extrovis eu ltd. - sugammadex sodium - neuromuskulær blokkade - alle andre terapeutiske produkter - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
欧州連合 -
ノルウェー語 -
EMA (European Medicines Agency)
bridion
merck sharp & dohme b.v. - sugammadex - neuromuskulær blokkade - alle andre terapeutiske produkter - reversering av nevromuskulær blokade indusert av rocuronium eller vecuronium. for peadiatric befolkning: sugammadex er bare anbefalt for rutinemessig reversering av rocuronium-blokade indusert hos barn og unge.
ノルウェー -
ノルウェー語 -
Statens legemiddelverk
emerade 500 mikrog
pharmaswiss ceska republika s.r.o. - adrenalintartrat - injeksjonsvæske, oppløsning i ferdigfylt penn - 500 mikrog
ノルウェー -
ノルウェー語 -
Statens legemiddelverk
emerade 150 mikrog
pharmaswiss ceska republika s.r.o. - adrenalintartrat - injeksjonsvæske, oppløsning i ferdigfylt penn - 150 mikrog
ノルウェー -
ノルウェー語 -
Statens legemiddelverk
emerade 300 mikrog
pharmaswiss ceska republika s.r.o. - adrenalintartrat - injeksjonsvæske, oppløsning i ferdigfylt penn - 300 mikrog